Published in Lancet on October 31, 2005
The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev (2008) 5.32
The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis (2008) 5.30
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med (2006) 2.60
Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol (2006) 2.48
Climate change and risk of leishmaniasis in north america: predictions from ecological niche models of vector and reservoir species. PLoS Negl Trop Dis (2010) 2.21
A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis (2013) 2.08
Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res (2011) 1.90
Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe (2013) 1.77
IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest (2009) 1.53
Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res (2007) 1.52
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin Vaccine Immunol (2012) 1.49
Sterol biosynthesis is required for heat resistance but not extracellular survival in leishmania. PLoS Pathog (2014) 1.48
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother (2006) 1.48
Nuclear envelope lamin-A couples actin dynamics with immunological synapse architecture and T cell activation. Sci Signal (2014) 1.47
Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species. BMC Genomics (2008) 1.47
Aberrant host defense against Leishmania major in the absence of SLPI. J Leukoc Biol (2014) 1.41
An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl Trop Dis (2012) 1.39
Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev (2014) 1.35
Global distribution maps of the leishmaniases. Elife (2014) 1.32
Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria. Nucleic Acids Res (2007) 1.30
Marring leishmaniasis: the stigmatization and the impact of cutaneous leishmaniasis in Pakistan and Afghanistan. PLoS Negl Trop Dis (2008) 1.29
Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum. J Biol Chem (2011) 1.29
Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods. Parasitol Res (2008) 1.28
Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res (2009) 1.27
Genome sequencing of the lizard parasite Leishmania tarentolae reveals loss of genes associated to the intracellular stage of human pathogenic species. Nucleic Acids Res (2011) 1.23
Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony. Parasitology (2007) 1.23
Visceral leishmaniasis in eastern Africa--current status. Trans R Soc Trop Med Hyg (2007) 1.23
Detection of Leishmania siamensis DNA in saliva by polymerase chain reaction. Am J Trop Med Hyg (2013) 1.23
Leishmaniasis. Postgrad Med J (2006) 1.23
Determinants for the development of visceral leishmaniasis disease. PLoS Pathog (2013) 1.22
Detection and identification of Leishmania species from clinical specimens by using a real-time PCR assay and sequencing of the cytochrome B gene. J Clin Microbiol (2007) 1.21
CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis (2010) 1.20
Comparisons of mutants lacking the Golgi UDP-galactose or GDP-mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major. Infect Immun (2007) 1.19
Identification of Leishmania spp. by molecular amplification and DNA sequencing analysis of a fragment of rRNA internal transcribed spacer 2. J Clin Microbiol (2011) 1.18
A novel organotellurium compound (RT-01) as a new antileishmanial agent. Korean J Parasitol (2009) 1.17
Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother (2009) 1.15
Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg (2009) 1.14
Comparative expression profiling of Leishmania: modulation in gene expression between species and in different host genetic backgrounds. PLoS Negl Trop Dis (2009) 1.14
Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol (2012) 1.13
Leishmaniasis. Postgrad Med J (2007) 1.13
The stage-regulated HASPB and SHERP proteins are essential for differentiation of the protozoan parasite Leishmania major in its sand fly vector, Phlebotomus papatasi. Cell Microbiol (2010) 1.13
gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun (2008) 1.13
Simultaneous gene expression profiling in human macrophages infected with Leishmania major parasites using SAGE. BMC Genomics (2008) 1.13
Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun (2008) 1.13
The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends Parasitol (2014) 1.10
Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int J Parasitol (2007) 1.09
Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot Cell (2006) 1.09
Isotopomer profiling of Leishmania mexicana promastigotes reveals important roles for succinate fermentation and aspartate uptake in tricarboxylic acid cycle (TCA) anaplerosis, glutamate synthesis, and growth. J Biol Chem (2011) 1.09
Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg (2013) 1.07
Evaluation of a microculture method for isolation of Leishmania parasites from cutaneous lesions of patients in Peru. J Clin Microbiol (2007) 1.07
The genome sequence of Leishmania (Leishmania) amazonensis: functional annotation and extended analysis of gene models. DNA Res (2013) 1.06
Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008. PLoS One (2011) 1.06
In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. PLoS Negl Trop Dis (2011) 1.05
Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect Immun (2007) 1.04
Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon. Emerg Infect Dis (2014) 1.04
Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis. Mar Drugs (2010) 1.04
Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg (2010) 1.04
Toll-like receptors in leishmania infections: guardians or promoters? J Parasitol Res (2012) 1.03
Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug. Ther Clin Risk Manag (2008) 1.02
Genetic evidence of functional ficolin-2 haplotype as susceptibility factor in cutaneous leishmaniasis. PLoS One (2012) 1.02
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis (2009) 1.01
Diagnostic performance of filter paper lesion impression PCR for secondarily infected ulcers and nonulcerative lesions caused by cutaneous leishmaniasis. J Clin Microbiol (2010) 1.01
Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model. Vet Res (2011) 1.00
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles. J Med Chem (2010) 1.00
High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery. PLoS Negl Trop Dis (2013) 1.00
Identification of new antileishmanial leads from hits obtained by high-throughput screening. Antimicrob Agents Chemother (2011) 1.00
Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol Res (2012) 1.00
Copaiba Oil: An Alternative to Development of New Drugs against Leishmaniasis. Evid Based Complement Alternat Med (2011) 0.99
Consecutive cutaneous and visceral leishmaniasis manifestations involving a novel Leishmania species in two HIV patients in Thailand. Am J Trop Med Hyg (2012) 0.99
Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One (2011) 0.99
First isolation of Leishmania from Northern Thailand: case report, identification as Leishmania martiniquensis and phylogenetic position within the Leishmania enriettii complex. PLoS Negl Trop Dis (2014) 0.98
Intracellular eukaryotic parasites have a distinct unfolded protein response. PLoS One (2011) 0.98
Intracellular targeting specificity of novel phthalocyanines assessed in a host-parasite model for developing potential photodynamic medicine. PLoS One (2011) 0.98
MicroRNA expression profile in human macrophages in response to Leishmania major infection. PLoS Negl Trop Dis (2013) 0.98
Antiparasitic therapy. Mayo Clin Proc (2011) 0.98
Synthetic sex pheromone attracts the leishmaniasis vector Lutzomyia longipalpis (Diptera: Psychodidae) to traps in the field. J Med Entomol (2009) 0.97
Colonisation resistance in the sand fly gut: Leishmania protects Lutzomyia longipalpis from bacterial infection. Parasit Vectors (2014) 0.96
In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis. PLoS One (2013) 0.95
Oligopeptidase B deficient mutants of Leishmania major. Mol Biochem Parasitol (2010) 0.95
DNA Vaccines against Protozoan Parasites: Advances and Challenges. J Biomed Biotechnol (2007) 0.95
Induction of a stringent metabolic response in intracellular stages of Leishmania mexicana leads to increased dependence on mitochondrial metabolism. PLoS Pathog (2014) 0.95
Characterization of metabolically quiescent Leishmania parasites in murine lesions using heavy water labeling. PLoS Pathog (2015) 0.94
Engagement of NKG2D on bystander memory CD8 T cells promotes increased immunopathology following Leishmania major infection. PLoS Pathog (2014) 0.94
Leishmania OligoC-TesT as a simple, rapid, and standardized tool for molecular diagnosis of cutaneous leishmaniasis in Peru. J Clin Microbiol (2009) 0.94
Characterization of the RNA polymerase II and III complexes in Leishmania major. Int J Parasitol (2006) 0.94
Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg (2012) 0.94
Antileishmanial, antitrypanosomal, and cytotoxic screening of ethnopharmacologically selected Peruvian plants. Parasitol Res (2011) 0.93
Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis (2011) 0.93
Deception and manipulation: the arms of leishmania, a successful parasite. Front Immunol (2014) 0.93
Whole chromosome aneuploidy: big mutations drive adaptation by phenotypic leap. Bioessays (2012) 0.93
Leishmania-specific surface antigens show sub-genus sequence variation and immune recognition. PLoS Negl Trop Dis (2010) 0.93
Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements. Infect Dis Poverty (2014) 0.93
Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species. PLoS Negl Trop Dis (2012) 0.93
Detection and characterization of Leishmania (Leishmania) and Leishmania (Viannia) by SYBR green-based real-time PCR and high resolution melt analysis targeting kinetoplast minicircle DNA. PLoS One (2014) 0.93
Regulation of immunity during visceral Leishmania infection. Parasit Vectors (2016) 0.92
Leishmania pifanoi proteoglycolipid complex P8 induces macrophage cytokine production through Toll-like receptor 4. Infect Immun (2008) 0.92
Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes. Antimicrob Agents Chemother (2007) 0.92
Leishmania donovani infection causes distinct epigenetic DNA methylation changes in host macrophages. PLoS Pathog (2014) 0.92
Reconstructing historical changes in the force of infection of dengue fever in Singapore: implications for surveillance and control. Bull World Health Organ (2008) 1.91
Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis (2006) 1.62
Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61
Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum. Am J Trop Med Hyg (2002) 1.56
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis (2003) 1.46
Multiple hybrid genotypes of Leishmania (viannia) in a focus of mucocutaneous Leishmaniasis. Am J Trop Med Hyg (2007) 1.41
Rapid detection of Leishmania infantum infection in dogs: comparative study using an immunochromatographic dipstick test, enzyme-linked immunosorbent assay, and PCR. J Clin Microbiol (2002) 1.40
Extinction of experimental Triatoma infestans populations following continuous exposure to dogs wearing deltamethrin-treated collars. Am J Trop Med Hyg (2006) 1.36
Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg (2008) 1.34
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother (2003) 1.29
Are insecticide-impregnated dog collars a feasible alternative to dog culling as a strategy for controlling canine visceral leishmaniasis in Brazil? Int J Parasitol (2004) 1.29
Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother (2005) 1.24
Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp. Infect Immun (2002) 1.22
Predicting geographic variation in cutaneous leishmaniasis, Colombia. Emerg Infect Dis (2004) 1.18
Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg (2002) 1.17
Could the Chagas disease elimination programme in Venezuela be compromised by reinvasion of houses by sylvatic Rhodnius prolixus bug populations? Trop Med Int Health (2006) 1.16
A continental risk map for malaria mosquito (Diptera: Culicidae) vectors in Europe. J Med Entomol (2002) 1.16
Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis (2007) 1.14
Indoor and peridomestic transmission of American cutaneous leishmaniasis in northwestern Argentina: a retrospective case-control study. Am J Trop Med Hyg (2003) 1.14
Canine leishmaniasis: novel strategies for control. Trends Parasitol (2002) 1.12
Chagas disease control: deltamethrin-treated collars reduce Triatoma infestans feeding success on dogs. Trans R Soc Trop Med Hyg (2005) 1.11
Amplification of human DNA by primers targeted to Leishmania kinetoplast DNA and post-genome considerations in the detection of parasites by a polymerase chain reaction. Am J Trop Med Hyg (2005) 1.10
Lessons from a national survey of Chagas disease transmission risk in Colombia. Trends Parasitol (2005) 1.09
Etiologic agent of an epidemic of cutaneous leishmaniasis in Tolima, Colombia. Am J Trop Med Hyg (2008) 1.06
Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg (2005) 1.05
Malaria in Britain: past, present, and future. Proc Natl Acad Sci U S A (2003) 1.05
Leishmania (Viannia) infection in the domestic dog in Chaparral, Colombia. Am J Trop Med Hyg (2011) 1.02
Natural infection of Phlebotomus argentipes with Leishmania and other trypanosomatids in a visceral leishmaniasis endemic region of Nepal. Trans R Soc Trop Med Hyg (2009) 0.97
Murine model of chronic L. (Viannia) panamensis infection: role of IL-13 in disease. Eur J Immunol (2010) 0.97
[Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002]. Biomedica (2003) 0.96
Resistance to oxidative stress is associated with metastasis in mucocutaneous leishmaniasis. J Infect Dis (2006) 0.95
Performance of OptiMAL(R) in the diagnosis of Plasmodium vivax and Plasmodium falciparum infections in a malaria referral center in Colombia. Mem Inst Oswaldo Cruz (2002) 0.94
Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol (2012) 0.94
Leishmania panamensis transmission in the domestic environment: the results of a prospective epidemiological survey in Santander, Colombia. Biomedica (2006) 0.93
Comparative protein profiling identifies elongation factor-1beta and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis. Mol Biochem Parasitol (2005) 0.91
Triatoma dimidiata infestation in Chagas disease endemic regions of Guatemala: comparison of random and targeted cross-sectional surveys. PLoS Negl Trop Dis (2011) 0.89
Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis. J Infect Dis (2007) 0.89
Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro. J Parasitol (2005) 0.88
Human macrophage response to L. (Viannia) panamensis: microarray evidence for an early inflammatory response. PLoS Negl Trop Dis (2012) 0.88
Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis. Antimicrob Agents Chemother (2008) 0.87
Evaluation of PCR as a diagnostic mass-screening tool to detect Leishmania (Viannia) spp. in domestic dogs (Canis familiaris). J Clin Microbiol (2003) 0.86
Domestic dog ownership: a risk factor for human infection with Leishmania (Viannia) species. Trans R Soc Trop Med Hyg (2003) 0.86
Pupal surveys for Aedes aegypti surveillance and potential targeted control in residential areas of Mérida, México. J Am Mosq Control Assoc (2008) 0.85
Establishing two-dimensional gels for the analysis of Leishmania proteomes. Proteomics (2002) 0.83
The transmission dynamics of canine American cutaneous leishmaniasis in Huánuco, Peru. Am J Trop Med Hyg (2003) 0.82
Mapping the proteome of Leishmania Viannia parasites using two-dimensional polyacrylamide gel electrophoresis and associated technologies. Biomedica (2003) 0.79
Leishmania (Viannia) spp. dissemination and tissue tropism in naturally infected dogs (Canis familiaris). Trans R Soc Trop Med Hyg (2002) 0.79
Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol (2004) 0.78
Polymorphisms in cg2 and pfcrt genes and resistance to chloroquine and other antimalarials in vitro in Plasmodium falciparum isolates from Colombia. Trans R Soc Trop Med Hyg (2004) 0.76
Effect of knowledge and economic status on sandfly control activities by householders at risk of cutaneous leishmaniasis in the subandean region of Huila department, Colombia. Biomedica (2006) 0.75